{ "market" : {"NAME" : "U.S.", "ID" : "us_market", "TZ" : "ET", "TZOFFSET" : "-18000", "open" : "1259073019", "close" : "1259096419", "flags" : {}} , "STREAMER_SERVER" : "http://streamerapi.finance.yahoo.com","arrowAsChangeSign" : false,"throttleInterval": "1000"}
globenewswire

Ingen Signs Deal With Nation's Leading Mail-Order Provider of Medical Supplies

  • Press Release
  • Source: Ingen Technologies, Inc.
  • On 7:30 am EST, Wednesday February 18, 2009

YUCAIPA, Calif., Feb. 18, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Other OTC:ITEC.PK - News), announced today distribution and marketing contracts with the Ohio based Edgepark Medical Supplies.

Related Quotes

SymbolPriceChange
ITEC.PK0.010.00
Chart for INGEN TECHNOLOGIES
{"s" : "itec.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Edgepark started as a corner pharmacy in Garfield Heights, Ohio, in 1928. Since that time, the company has grown to become the nation's leading mail-order provider of medical supplies, with over 700 employees that provide a national distribution program of medical supplies with timeliness and accuracy through five state-of-the-art distribution facilities located throughout the United States (Cleveland, Ohio; Los Angeles, California; Dallas, Texas; Albany, New York; and Jacksonville, Florida).

Edgepark Medical Supplies has accepted Ingen as a vendor to provide Oxyview as a part of their medical supplies inventory, as well as has designed an initial marketing package to promote Oxyview. ``We look forward to working with Edgepark and assisting with their marketing efforts to sell Oxyview. This could be a very prosperous relationship for all parties involved,'' stated Thomas Neavitt, Chief Financial Officer of Ingen Technologies.

For more information please visit:

http://www.ingen-tech.com

https://www.edgepark.com/aboutedgepark/

About Ingen Technologies, Inc.

Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and successful licensing with the Food & Drug Administration, and has commenced domestic and global distribution with manufacture representative organizations, and OEM partners. In addition to selling its respiratory products within the global medical industry, the company is selling the same products within other industries that include aviation, automotive, emergency response, military and government transportation. The company holds a Device Manufacturing License with the State of California, Department of Public Health, Food and Drug Branch as it manufactures all of its respiratory products in the United States. There are 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide. Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact:

          Ingen Technologies, Inc.
Chris Wirth
909-790-7180
www.info@ingen-tech.com

Sponsored Links

Copyright © 2009 GlobeNewswire. All rights reserved. Redistribution of this content is expressly prohibited without prior written consent. GlobeNewswire makes no claims concerning the accuracy or validity of the information, and shall not be held liable for any errors, delays, omissions or use thereof.